Clinical Trial

Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistance

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 7, 2023 (before its estimated September 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
Cadonilimab combined with paclitaxel (albumin-bound) treat advanced gastric adenocarcinoma or esophagogastric junction adenocarcinoma with PD-(L)1 inhibitors resistance
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT06118645
Lead Sponsor China Medical University, China
Conditions Gastric Adenocarcinoma
Enrollment 40 participants
Start Date 2023-11-01
Primary Completion 2024-09-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2023-11-07